Deprescribing in action: relieving carer burden with HMR by Stafford, Andrew
Australian Pharmacist  November 2015  I  © Pharmaceutical Society of Australia Ltd.62
CONTINUING PROFESSIONAL DEVELOPMENT
MEDICATION REVIEW
Dr Andrew Stafford is Director of the Western 
Australian Dementia Training Study Centre, School of 
Pharmacy at Curtin University of Technology, Perth 
WA. He is also an accredited consultant pharmacist. 
LEARNING OBJECTIVES
After reading this article, pharmacists should be 
able to:
•	 Identify drug-related problems (DRPs)
•	 Develop a systematic and holistic approach to 
evaluate and address these DRPs
•	 Adopt best practice to make clinically sound 
recommendations to help resolve DRPs and 
achieve optimal patient care outcomes.
Competency standards (2010) addressed: 1.3, 2.1, 
2.2, 2.3, 4.2, 6.3, 7.1, 7.2.
































Deprescribing in action: 
relieving carer burden with 
HMR
BY DR ANDREW STAFFORD
An 85-year-old gentleman was referred for a home medicines review 
(HMR). The HMR was requested as he had recently been commenced on 
a Websterpak dose administration aid to assist his wife (as primary carer) 
manage his medicines. 
The referring general practitioner (GP) 
wanted to ensure that it was being used 
correctly. The referral also requested that 
the pharmacist comment on potential 
options to reduce the gentleman’s 
medicine burden. The patient’s medical 
history was significant for the following:
•	 Alzheimer’s disease
•	 gastro-oesophageal reflux disease 
(GORD)
•	 hypertension
•	 ischaemic heart disease (‘mild’ 
myocardial infarction (MI) 23 years 
ago)
•	 overactive bladder
•	 peripheral artery disease
•	 type 2 diabetes
•	 vitamin B12 deficiency.
His medications, as per the HMR referral, 
were as follows:
•	 aspirin EC 100 mg each morning
•	 cholecalciferol 25 mcg each morning 
•	 esomeprazole 20 mg each morning
•	 hydroxocobalamin 1000 mcg/mL s/c 
injection every 3 months
•	 glimepiride 1 mg each morning
•	 metoprolol 50 mg half twice daily
•	 risperidone 500 mcg at night
•	 simvastatin 10 mg at night
•	 solifenacin 5 mg at night
The patient’s wife also attended the HMR 
interview. Her major concern was that 
her husband was becoming increasingly 
reluctant to take his medicines. 
The risperidone was introduced around 
a month ago to manage his agitation 
around taking his medicines. 
The patient’s wife had only administered 
the risperidone for approximately 
one week, before ceasing it herself 
because she felt that it was ineffective 
for managing his behaviour, and she 
associated it with causing a number 
of adverse effects. She believed that it 
made her husband excessively drowsy – 
so much so that he experienced urinary 
incontinence because he did not wake 
up, and he fell out of bed three times 
that week which had never happened 
before. Her concern was that his 
incontinence was worsening, such that 
he now wore pads at all times. He had 
experienced urge incontinence for 
many years which had been adequately 
controlled with solifenacin until 
recently. However, he was now finding 
that he had reduced time between 
experiencing an urge to urinate and 
losing urine, and had several episodes of 
incontinence throughout the day. 
Aside from this, the medicines in the 
Websterpak dose administration aid were 
given as intended, although the patient 
regularly refused to take many of them.
From their perspective, his 
cardiovascular conditions were not 
causing any issues as he was able 
to mobilise without anginal pain or 
claudication. Both the patient and his 
wife recalled him experiencing two 
episodes of mild hypoglycaemia in the 
past month, which were appropriately 
managed with no adverse outcomes. 
His GORD symptoms were well 
controlled, although previous attempts 
at ceasing esomeprazole resulted in a 
return of symptoms.
Results of blood tests performed a month 
before the HMR are shown in Table 1. 
At this time, his blood pressure was 
138/57 mmHg, pulse 54 bpm, and he 
weighed 85 kg.
Assessment
This article provides an overview of 
the considerations made regarding the 
two primary concerns of the patient’s 
carer, i.e. her husband’s reluctance to 
take his medicines and his continence 
management. 
Medicine administration
The principles of behavioural strategies to 
encourage people with dementia to take 
their medicines are generally no different 
to techniques employed to assist them 
perform other activities of daily living.1 
These have been described extensively 
elsewhere.2,3 Briefly, a person-centred 
approach should be utilised, involving 
identification of the probable reasons for 
behaviours that occur during medicine 
administration, and addressing these 
reasons using an individualised plan.4 
Techniques utilised may involve the use 
of simple, appropriate language and 
tone, simple instructions, appropriate 
non-verbal cues, and not arguing.
Medicine burden
A second aspect to reducing the burden of 
medicine administration for people with 
dementia and their carers is minimisation of 
the number of medicines taken.5 This was 
particularly important in this case, given 
the patient’s reluctance to take medicines. 
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To achieve this aim, the concept of 
deprescribing was utilised. Deprescribing 
has been defined as ‘the systematic 
process of identifying and discontinuing 
drugs in instances in which existing or 
potential harms outweigh existing or 
potential benefits within the context of an 
individual patient’s care goals, current level 
of functioning, life expectancy, values, and 
preferences’.6 For the patient discussed in 
this case, the potential for each medicine 
to be discontinued was reviewed in 
consideration of its potential benefits and 
toxicities, the patient’s life expectancy, 
and the patient and his wife’s wishes.
There is considerable variation in the 
estimated life expectancy of a person 
with Alzheimer’s disease, with published 
data ranging from 3–12 years.7 The man 
discussed in this case study had 
moderate dementia and it was assumed 
that he may live for around five years. 
The following summary considers 
the issues regarding his medicine 
regimen in terms of his anticipated life 
expectancy and duration of treatment.
Metoprolol
Australian guidelines currently 
recommend that a beta-blocker should 
be prescribed for most patients after 
an MI unless contraindicated (level I 
evidence, grade A recommendation).8 
However, there is debate as to the 
appropriate duration of beta-blocker 
treatment post-MI in patients with 
normal left ventricular function who 
are not experiencing angina, or who 
require beta-blocker treatment for 
hypertension or dysrhythmia.9 A recent 
systematic review of the evidence for 
beta-blocker use post-MI identified that 
beta-blockers reduce total mortality, 
re-infarction and sudden cardiac death 
mainly within the first three years of use, 
with the majority of benefit occurring 
in the first year.9 As the man discussed 
in this case had a single event over 
20 years ago, and did not appear to have 
issues with left ventricular dysfunction 
(i.e. no history of pulmonary oedema), 
no myocardial ischaemia or arrhythmias, 
it was considered that metoprolol could 
potentially be withdrawn.
Aspirin
Similarly, Australian guidelines 
recommend that all patients should take 
75–150 mg daily post-MI indefinitely 
unless contraindicated (level I 
evidence, grade A recommendation).8 
However, there is little evidence to guide 
the optimal duration of aspirin following 
an MI, and there is evidence that aspirin 
cessation is associated with an increased 
risk of MI when used for secondary 
prevention.10 Consequently, there were 
less compelling arguments to cease 
aspirin at this time.
Simvastatin
Current guidelines recommend that 
statin therapy should be given to all 
patients post-MI irrespective of the 
patient’s cholesterol level.8 There is 
considerable evidence that older people 
benefit similarly from statin treatment 
as younger people.11,12 However, it is 
notable that the patient discussed in this 
case study was taking a very low dose of 
simvastatin, whilst a dose of 20–40 mg 
would be more appropriate based on 
recent US guidelines.13 If minimising 
medicines was not a focus of this HMR, 
it may have in fact been considered 
appropriate to increase the statin 
dose despite his current lipid profile. 
However, as there is no evidence nor 
plausible reason that cardiovascular risk 
would be substantially increased with 
statin cessation for the patient in this 
case, simvastatin was also be considered 
for potential discontinuation. 
Cholecalciferol
Current Australian guidelines recommend 
that people over the age of 70 who 
receive less than the optimal level of sun 
exposure should receive at least 800 IU 
of vitamin D per day as part of a fracture 
risk management plan.14 However, there 
is some debate as to the benefits of 
vitamin D supplementation, with a recent 
meta-analysis finding that vitamin D 
supplementation without calcium reduces 
the relative risk of hip fracture by less 
than 15%, which is not considered to be 
Table 1. Laboratory results from two weeks ago
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clinically significant.15 In consideration 
of the relatively small benefit of 
cholecalciferol supplementation, it too 
was identified as a medicine that could 
potentially be ceased.
Glimepiride
Whilst the general HbA1c target for 
people with diabetes is ≤53 mmol/
mol, there are a number of factors 
that influence the appropriateness of 
stringent blood glucose control and 
treatment targets. The relatively limited 
life expectancy of the patient discussed 
in this case, in addition to the potentially 
severe adverse outcomes resulting from 
an episode of hypoglycaemia, indicate 
that a target HbA1c of somewhat 
greater than 53 mmol/mol would be 
acceptable.16 As his most recent HbA1c 
was <53 mmol/mol, it was likely that 
adequate glucose control could be 
achieved without glimepiride.
Incontinence
Urinary incontinence, particularly urge 
incontinence, is very common in people 
with dementia, and its prevalence 
increases as dementia progresses.17 
As with people who do not have 
dementia, management strategies for 
urinary incontinence are multi-factorial 
and may involve behavioural, physical, 
pharmacological, and occasionally 
surgical techniques.18 Dementia 
presents particular challenges with 
urge incontinence management, as 
several effective and frequently used 
interventions either require the use of 
cognitive abilities that are diminished 
in dementia (e.g. bladder training), 
or may exacerbate cognitive impairment 
(urinary antimuscarinics).17 
For the man reviewed in this HMR, 
the lack of effectiveness of solifenacin, 
coupled with administration difficulties 
and potential adverse cognitive effects 
provided good reasons to cease 
it. However, as this would possibly 
exacerbate his urinary incontinence, 
an alternative management strategy 
needed to be formulated. In terms 
of pharmacological management, 
mirabegron is considered to be less 
likely to affect cognitive function 
than antimuscarinics,19 although 
currently there is no data regarding 
its use in people with dementia. As its 
effectiveness is approximately equivalent 
to antimuscarinics, and minimising 
medicines was a priority for the 
review, it was not considered to be an 
appropriate management option.
The most commonly used behavioural 
approaches for continence management 
for people with dementia involve 
prompted and timed voiding.17 
Both approaches generally rely on carer 
assistance, and focus on preventing urine 
loss rather than restoring normal bladder 
function. In prompted voiding, the 
person with dementia is regularly asked 
whether they need to urinate, whereas 
timed voiding involves presenting the 
person to the toilet at regular intervals. 
As both techniques require vigilance 
on behalf of the carer, a number of 
adaptations have been developed to 
reduce this additional burden, such as the 
use of programmable alarms and timers.18 
Recommendations and 
outcomes
To assist the wife with her husband’s 
regular refusal to take medicine, a referral 
to the Dementia Behaviour Management 
Advisory Service (DBMAS) was made. 
A DBMAS team member promptly 
reviewed the man and provided his wife 
with a number of strategies to assist her 
to manage his behaviour. Following this 
positive interaction, it was suggested to 
the GP that risperidone was unnecessary 
at this time.
After a discussion with the man, his wife 
and the GP, a number of options were 
reviewed to minimise the man’s medicine 
burden. It was suggested that metoprolol 
and glimepiride be ceased, and his 
blood pressure and HbA1c monitored 
after two weeks and three months, 
respectively, to ensure that no adverse 
outcomes resulted from these accepted 
changes. Based on his recent lipid profile, 
simvastatin was also ceased as it was felt 
that it was not conferring substantial 
clinical benefit.
The man’s wife expressed a strong 
preference to continue aspirin, and it 
was recommended that a soluble 
dosage form be trialled to see if the 
man was more amenable to a solution 
over a tablet. Whilst liquid preparations 
of cholecalciferol are available, it was 
decided to also cease cholecalciferol as 
his recent vitamin D level was well above 
the recommended minimum. The man’s 
wife was also instructed on how to 
disperse esomeprazole tablets, should 
the man be more receptive to liquids.
To assist with continence management, 
the GP referred the man to a 
continence advisory service. It was 
also recommended that a withdrawal 
of solifenacin be trialled, based on its 
lack of effectiveness and potential to 
exacerbate his cognitive impairment.
Conclusion 
Medicine management is frequently 
challenging for older people, and the 
balance between the benefits and 
risks associated with pharmacotherapy 
changes as medical conditions progress. 
HMRs provide an ideal opportunity 
to ensure that all medicines taken are 
aligned with a person’s current goals of 
therapy, and can substantially assist in 
alleviating the burden associated with 
medicine management for older people. 
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1. Mrs Rose is an 84-year-old woman 
with moderate dementia. She has 
recently started to refuse a number 
of medicines that she has taken for 
several years when her husband 
attempts to administer them to her. 
Which ONE of the following is the 
MOST appropriate initial strategy to 
resolve this issue?
a) Explain in detail to her the benefits that 
each medicine provides.
b) Identify the potential reasons for her 
changed behaviour.
c) Commence a low dose of risperidone.
d) Cease all medicines that are 
regularly refused.
2. Which ONE of the following 
strategies is MOST consistent with 
the concept of deprescribing?
a) Discontinuing all medicines with high 
risk of adverse effects.
b) Ceasing all medicines that do not 
provide symptomatic benefit.
c) Discontinuing medicines with an 
unfavourable risk-benefit ratio.
d) Ensure that every medical condition 
is treated strictly according to current 
guidelines.
3. Which ONE of the following 
statements regarding the secondary 
prevention of myocardial infarction 
(MI) in older people is the LEAST 
appropriate?
a) There is no evidence that 
discontinuation of aspirin post-MI is 
associated with an increased risk of 
adverse outcomes.
b) Most of the benefits resulting from 
beta-blockers administered post-MI 
are realised within the first three years 
of use.
c) The risk of poor outcomes associated 
with hypoglycaemia generally 
outweighs the benefit of stringent 
blood glucose control (HbA1c 
≤53 mmol/mol).
d) Statins are generally as beneficial for 
secondary prevention of MI in older 
people as in younger people.
4. Considering the risk-benefit ratio 
and in light of no adverse effects 
to the patient, in which ONE of the 
following scenarios is the strategy 
of deprescribing the medicine cited 
LEAST likely to be of value?
a) A 96-year-old woman with a 15-year 
history of Alzheimer’s disease whose 
only medicine is alendronate for primary 
prevention of osteoporosis.
b) A 68-year-old woman with newly 
diagnosed type 2 diabetes whose 
only medicine is rosuvastatin for 
hypercholesterolaemia.
c) A 62-year-old man with metastatic small 
cell lung cancer who is taking ramipril 
for hypertension.
d) A 74-year-old man with no significant 
medical history whose only medicine is 
low-dose aspirin.
5. Which ONE of the following 
statements regarding urinary 
incontinence in people with 
dementia is the MOST appropriate? 
a) Bladder training is an effective 
management strategy in advanced 
dementia.
b) Prompted voiding requires minimal 
commitment from carers to be effective.
c) Mirabegron has been shown to be safe 
and effective in people with dementia. 
d) Multi-factorial strategies are generally 
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